Sabril, Kigabeq (vigabatrin) is a small molecule pharmaceutical. Vigabatrin was first approved as Sabril on 2009-08-21. It is used to treat complex partial epilepsy, epilepsy, and infantile spasms in the USA. It has been approved in Europe to treat infantile spasms and partial epilepsies. The pharmaceutical is active against 4-aminobutyrate aminotransferase, mitochondrial. In addition, it is known to target vesicular inhibitory amino acid transporter.
|Indication||complex partial epilepsy, epilepsy, infantile spasms, partial epilepsies|